Multikinase inhibitor Nexavar's (sorafenib) failure in first-line non-small-cell lung cancer came as little surprise to investors of Onyx Pharmaceuticals Inc., who have their eyes trained on much-anticipated Phase IIb data for multiple myeloma drug carfilzomib, which, if positive, could be enough for an FDA filing late this year. (BioWorld Today) Read More
